Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Inhibiting epidermal growth factor receptor (EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and clinical research within the field. Second-generation EGFR-targeted agents that aim to further improve patient outcomes are now in preclinical and clinical trials. This review discusses four promising agents that are currently being studied in NSCLC: EKB-569, HKI-272, CI-1033, and ZD6474.
Sequist
Lecia V
LV
Massachusetts General Hospital Cancer Center, 32 Fruit Street, Yawkey Suite 7B, Boston, Massachusetts 02114, USA. lvsequist@partners.org
D000634:Aminoquinolines; D000814:Aniline Compounds; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009025:Morpholines / Q000627:therapeutic use; D009930:Organic Chemicals / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use
D000634:Aminoquinolines; D000814:Aniline Compounds; D000970:Antineoplastic Agents; D009025:Morpholines; D009930:Organic Chemicals; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D011804:Quinolines; C420268:Canertinib; D066246:ErbB Receptors; C487932:neratinib; C413879:EKB 569; C452423:vandetanib